- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:54 | Xilio Therapeutics appoints Cheryl Blanchard to board | 1 | Investing.com | ||
| 13:36 | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12:35 | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 23.03. | Xilio plans mid-2026 IND filing for cancer therapy XTX501 | 2 | Investing.com | ||
| 23.03. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 23.03. | Xilio plant IND-Antrag für Krebstherapie XTX501 für Mitte 2026 | 2 | Investing.com Deutsch | ||
| 23.03. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 23.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results | 325 | GlobeNewswire (Europe) | XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class... ► Artikel lesen | |
| 23.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 17.03. | Xilio Therapeutics to present data on masked cancer therapy at AACR | 2 | Investing.com | ||
| 17.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.03. | Xilio Therapeutics implements 1-for-14 reverse stock split | 4 | Investing.com | ||
| 12.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces 1-for-14 Reverse Stock Split | 250 | GlobeNewswire (Europe) | WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people... ► Artikel lesen | |
| 09.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 24.02. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.02. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.02. | Xilio Therapeutics prices $40M stock offering | 2 | Seeking Alpha | ||
| 12.02. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pricing of Underwritten Offering | 3 | GlobeNewswire (USA) |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,000 | -1,71 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,990 | +110,18 % | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| EVOTEC | 5,570 | +0,54 % | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,220 | +14,79 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| BIONTECH | 85,95 | +1,96 % | BioNTech-Aktie: Wann geht's wieder über 100 Euro? | BioNTech hat neue klinische Daten zu einem wichtigen Krebsmedikament veröffentlicht und damit erneut Fortschritte in seiner Onkologie-Pipeline demonstriert. Für Investoren sind solche Studiendaten entscheidend... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,725 | -0,67 % | Recursion-CEO erläutert KI-Strategie zur Beschleunigung der Medikamentenentwicklung | ||
| GENMAB | 237,90 | -4,23 % | Genmab Reports Strong Q1 DARZALEX Sales Near $4 Bln | WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) on Tuesday reported global net trade sales of $3.964 billion for DARZALEX (daratumumab) in the first quarter of 2026, according to company announcements.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 315,01 | -7,27 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,365 | +9,24 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| VALNEVA | 2,610 | -1,66 % | Guggenheim senkt Kursziel für Valneva-Aktie wegen Lyme-Impfstoff auf 11 US-Dollar | ||
| ADMA BIOLOGICS | 10,600 | -0,38 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| BEAM THERAPEUTICS | 30,050 | -2,04 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 6,660 | +13,75 % | Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update | In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was... ► Artikel lesen | |
| CG ONCOLOGY | 65,27 | -3,65 % | CG Oncology, Inc. - 8-K, Current Report | ||
| TYRA BIOSCIENCES | 34,990 | +0,14 % | This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 8,425 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.